Last, activation of NAD+ by NMN treatment successfully rescued intracellular levels of ATP and axoplasmic fluidity and reduced the pathological aggregation of TDP-43 in motor neurons derived from a patient with ALS and the TDP-43N390D mutation. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.